secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031372
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Therapeutics Q3 2022: Revenue $9K, cash $0.5M, substantial going concern doubt
--------------------------------------------------------------------------------

- Cash and equivalents $0.5M; company says cash insufficient for next 12 months, raising substantial going concern doubt.
- Total revenues $9,000 vs $24,000 prior-year quarter; R&D $0.2M, G&A $1.4M flat.
- Borrowed additional $1.0M under $13.16M Secured Note from Juvenescence; $1.5M remaining, draws at Juvenescence's discretion.
- $8M principal under earlier 2020 Loan Agreement due March 2023; Secured Note matures Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315222031372/0001493152-22-031372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315222031372/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer